Journal of Histochemistry and Cytochemistry, Vol. 51, 493-501, April 2003, Copyright © 2003, The Histochemical Society, Inc.


ARTICLE

Human Kallikrein 13 Expression in Normal Tissues: An Immunohistochemical Study

Constantina D. Petrakia, Vassiliki N. Karavanaa, and Eleftherios P. Diamandisb
a Department of Pathology, Evangelismos Hospital, Athens, Greece
b Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Correspondence to: Eleftherios P. Diamandis, Dept. of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. E-mail: ediamandis@mtsinai.on.ca


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

The human tissue kallikrein 13 gene (KLK13), encoding for hK13 protein, was recently cloned and characterized. Here we describe the immunohistochemical (IHC) localization of hK13 in normal human tissues and compare it with the expression of two other kallikreins, hK6 and hK10. We performed the streptavidin–biotin IHC method on 204 paraffin blocks from archival, current, and autopsy material prepared from almost every normal human tissue, using a polyclonal and a monoclonal hK13 antibody. The staining was cytoplasmic and both antibodies yielded similar results. The hK13 protein was revealed in a variety of tissues, mainly in glandular epithelia. Other epithelia that expressed hK13 included the urothelium, the spermatic epithelium, and the epithelium of the choroid plexus. hK13 was intensely immunoexpressed by some endocrine organs, such as the adenohypophysis, the thyroid gland, the parathyroid glands, the adrenal medulla, the Leydig cells of the testis, and the cells of the endocrine pancreas. Immunoreactivity was also observed in the primordial follicles, the corpus luteum, and sparse luteinized cells in the stroma of the ovary, the trophoblastic cells of the placenta, the Hassall's corpuscles of the thymus, and chondrocytes. Nerves and ganglia of the peripheral nervous system, and both neurons and glial cells in the central nervous system, were positive. In short, hK13 was expressed by many glandular epithelia, some endocrine organs, and some specialized epithelia and cells. Comparison of these data with hK6 and hK10 expression suggests that the three kallikreins have a similar IHC pattern in normal human tissues. (J Histochem Cytochem 51:493–501, 2003)

Key Words: human kallikreins, human kallikrein 13, immunohistochemical, expression, serine proteases, cancer biomarkers, epithelial cell markers


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

HUMAN TISSUE KALLIKREINS are members of a large multigene family of 15 serine proteases (Bhoola et al. 1992 ; Diamandis et al. 2000b ; Yousef and Diamandis 2001 ). An international group of investigators has agreed on unified nomenclature for the genes designated as KLK1–KLK15 and their encoded proteins hK1–hK15 (Diamandis et al. 2000a ). hK3 (prostate-specific antigen, PSA) and hK2 are relatively prostate-specific and have already found important applications as biomarkers for the diagnosis and monitoring of prostate cancer (McCormack et al. 1995 ; Chu 1997 ; Rittenhouse et al. 1998 ). It is worth mentioning, however, that hK3 and hK2 proteins and mRNA have been found in significant amounts in the female breast and at lower levels in many other tissues (Black and Diamandis 2000 ; Black et al. 2000 ). The remaining kallikreins are not tissue-specific, although certain genes are preferentially expressed in specific organs (Diamandis et al. 2000b ; Yousef and Diamandis 2001 ). The human tissue kallikrein 13 gene (KLK13), encoding for hK13 protein, is a recently cloned gene that was originally named kallikrein-like gene 4 (KLK-L4) (Yousef et al. 1999 , Yousef et al. 2000 ).

Very few studies have examined human kallikrein expression by IHC in normal or diseased tissues. In our previous reports, we described hK6 and hK10 expression in a variety of normal tissues by IHC (Petraki et al. 2001 , Petraki et al. 2002 ) and observed that both kallikreins had a similar IHC pattern of expression. Here we describe the IHC localization of hK13 in diverse human tissues and correlate these data with the expression of hK6 and hK10.


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Representative samples from almost all normal human tissues were studied by IHC. Parts of an organ with different histology (e.g., stomach fundus, body, antrum) were examined separately. Tissues that exist in several organs (e.g., fat, muscle, vessels, peripheral nerves, ganglia) were not studied separately. A total of 204 paraffin blocks were examined. From these, 170 represented archival or current material from 137 cases and the other 34 samples were autopsy material from two cases. The archival and the current material were biopsy or surgical specimens (Table 1). Most but not all of these samples were examined previously for hK6 and hK10 immunoexpression (Petraki et al. 2001 , Petraki et al. 2002 ).


 
View this table:
[in this window]
[in a new window]
 
Table 1. Tissues studied for the immunohistochemical expression of human kallikrein 13

The IHC staining was performed on 4-µm-thick paraffin sections of tissues fixed in buffered formalin, according to a streptavidin–biotin–peroxidase protocol using the DAKO LSAB+Kit Peroxidase (DAKO; Glostrup, Denmark). An hK13-specific rabbit polyclonal antibody (1:500) and two hK13 (2-17 and 11C1) mouse monoclonal antibodies (MAbs: 1:150 and 1:50, respectively) raised against full-length recombinant hK13 protein produced in yeast were used. The recombinant hK13 protein was produced and purified by HPLC as previously described for hK10 protein (Luo et al. 2001b ). None of these antibodies crossreacted with other kallikreins in ELISA assays (Kapadia et al. in press ). Staining procedures included deparaffinization in warm xylene for 5 min with two changes of xylene at room temperature (RT), followed by rehydration by transfer through graded alcohols. Endogenous peroxidase activity was blocked with 0.5% H2O2 in methanol for 10 min. The sections were pretreated with 10 mmol/liter citrate buffer (pH 6.1) in a microwave oven for 5 min and were incubated overnight at 4C with the hK13 primary rabbit polyclonal (PAb) and mouse MAb in 3% BSA. After two washes of the sections in 50 mM Tris buffer (pH 7.6), the biotinylated link (DAKO; Carpinteria, CA) was applied for 15 min and a streptavidin-peroxidase conjugate followed for another 15 min. The enzymatic reaction was developed in a freshly prepared solution of 3,3'-diaminobenzidine tetrahydrochloride using DAKO Liquid DAB Substrate-Chromogen Solution for 10 min (brown color). The sections were then counterstained with hemalum, dehydrated, cleared in xylene, and mounted. The staining pattern, the distribution of the immunostaining in each tissue, and the intensity of the staining were studied in detail.

In selected tissues the primary polyclonal antibody was replaced by a nonimmune rabbit serum (1:500) in 3% BSA to evaluate nonspecific binding. For the same reason, an immunoabsorption test was also performed in which the primary hK13 antibody was incubated for 1 hr at RT with an excess of recombinant hK13 antigen.


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

The hK13 immunoreactivity, using the polyclonal antibody and the two MAbs, was generally localized in the cytoplasm. All antibodies revealed the same distribution of the antigen in all tissues. Replacement of the primary polyclonal antibody with nonimmune rabbit serum and the immunoabsorption test resulted in disappearance of the immunostaining in all tissues examined.

In our previous studies we did not find any major differences between the immunolocalization of hK6 and hK10 in normal human tissues. It is worth mentioning that, in the present study, hK13 had, in general, a similar IHC distribution as the other two kallikreins. The protein was revealed in a variety of tissues, indicating that it is not tissue-specific.

The hK13 protein was immunoexpressed mainly by glandular epithelia. The gastric mucosa expressed the kallikrein focally in all cell types (Fig 1A). A characteristic supranuclear, droplet-like, and brush border localization was observed in the duodenum (Fig 1B) and the other parts of the small intestine (Fig 1C). All parts of the large intestine (Fig 1D) and the appendix (Fig 1E) showed strong and diffuse immunoexpression in both the enterocytes and the goblet cells. The major and minor salivary glands (Fig 1F), as well as the submucosal glands of the pharynx and the esophagus, expressed the antigen. The epithelium of the pancreatic (Fig 1G) and bile duct system (Fig 1H), and also of the gallbladder (Fig 1I), was positive. Strong cytoplasmic staining was observed in the epithelium of the bronchial tree (Fig 1J). All glands of the upper and lower respiratory system (nasal, sinusoidal, laryngeal, tracheal, and bronchial) were strongly positive (Fig 1K). The epithelium of the eccrine and apocrine glands of the skin was also strongly positive (Fig 1L). The glandular epithelia in the genitourinary tract and in the male and female reproductive systems expressed hK13. The urinary tubuli of the kidney expressed the protein diffusely (Fig 2A). Immunoexpression in the epithelium of the prostate (Fig 2B), the ejaculatory ducts, the seminal vesicles, the rete testis, the epididymis (Fig 2C), and the spermatic duct (Fig 2D) was diffuse and strong. The staining in the surface epithelium of the ovary, epithelium of the fallopian tubes, breast (Fig 2E and Fig 2F), and endometrium (Fig 2G) was strong, but in some cases focal. No differences were observed during the course of the menstrual cycle. The columnar epithelium of the endocervix showed weaker and more focal distribution, and foci of immature squamous metaplasia also expressed the antigen (Fig 2H).



View larger version (99K):
[in this window]
[in a new window]
 
Figure 1. (A) Cytoplasmic hK13 immunoexpression in pyloric glands of the gastric mucosa, MAb clone 2–17. (B) Cytoplasmic and brush border hK13 immunoexpression in absorptive and goblet cells in the villous and glandular epithelium of the duodenum, MAb clone 2–17. (C) Supranuclear and brush border hK13 immunoexpression in absorptive and goblet cells in the villous and glandular epithelium of the ileum, MAb clone 2–17. (D) Cytoplasmic hK13 immunoexpression in absorptive and goblet cells in the epithelium of the colon, MAb clone 2–17. (E) Cytoplasmic hK13 immunoexpression in absorptive and goblet cells in the epithelium of the appendix, polyclonal antibody. (F) Cytoplasmic hK13 immunostaining in the duct epithelium of the parotid gland; positivity in some acinar cells, polyclonal antibody. (G) Cytoplasmic hK13 positivity in the epithelium of medium-sized ducts of the pancreas/absence of immunostaining in the acinar epithelium, MAb clone IICI. (H) Cytoplasmic hK13 expression in the epithelium of a portal bile duct of the liver; absence of expression in the hepatocytes, MAb clone 2–17. (I) Supranuclear cytoplasmic hK13 immunoexpression in the epithelium of the gallbladder, MAb clone 2–17. (J) Cytoplasmic hK13 immunoexpression in the epithelium of the bronchus, MAb clone IIC1. (K) Intense cytoplasmic hK13 staining in serous alveoli and in excretory ducts of the submucosal bronchial glands; weaker staining in mucous alveoli, polyclonal antibody. (L) Cytoplasmic hK13 staining in the duct epithelium of subcutaneous eccrine glands, MAb clone 11C1. All magnifications x200.



View larger version (98K):
[in this window]
[in a new window]
 
Figure 2. (A) Supranuclear cytoplasmic hK13 immunoexpression in the epithelium of the distal convoluted tubules in the cortical area of the kidney, MAb clone 2–17. (B) Cytoplasmic hK13 immunostaining in the secretory cells in the peripheral zone of the prostate gland, MAb clone 11C1. (C) Cytoplasmic hK13 immunoexpression in the epithelium of the epididymis, MAb clone 11C1. (D) Brush border and cilia hK13 immunostaining in the epithelium of the ductus deferens, near the junction with the epididymis, MAb clone 2–17. (E) Cytoplasmic hK13 immunoexpression in the columnar cells of the ductal and lobuloalveolar structures in the breast and positivity in luminal secretions as well, polyclonal antibody. (F) Cytoplasmic hK13 immunostaining in the columnar cells in the breast; no staining in the myoepithelial cells, MAb clone 11C1. (G) Cytoplasmic hK13 immunoexpression in the surface and glandular epithelium of the endometrium in the secretory phase of the menstrual cycle, polyclonal antibody. (H) Cytoplasmic hK13 immunoexpression in the columnar epithelium of the endocervix (coexistence of immature squamous metaplasia), MAb clone 11C1. (I) hK13 immunoexpression in the umbrella cells of the urothelium of the urinary bladder, MAb clone 2–17. (J) Weak hK13 immunostaining in the spermatic epithelium of the testis, MAb clone 2–17. (K) Strong cytoplasmic hK13 positivity in the choroid plexus epithelium, MAb clone 2–17. (L) Pituitary gland, hK13-positive endocrine cells (corticotrophs) in the adenohypophysis, MAb clone 11C1. Magnifications x200.

Weak and diffuse immunoexpression of hK13 by the squamous epithelia in the different organs of the human body was not considered as positive. Other than glandular epithelia, epithelia that expressed hK13 were the urothelium, with immunolocalization mainly in the superficial cells (Fig 2I), the spermatic epithelium (Fig 2J), and the epithelium of the choroid plexus (Fig 2K).

The hK13 protein was intensely immunoexpressed by some endocrine organs and showed a similar distribution to that of the other two kallikreins. The lactotrophs and the corticotrophs of the anterior lobe of the pituitary (Fig 2L), the epithelium of the thyroid follicles, mainly in foci of hyperplasia oxyphilic metaplasia (Fig 3A), the cells, mainly oxyphilic, in the parathyroid glands (Fig 3B), the adrenal medulla, the Leydig cells of the testis (Fig 3C), and the cells of the endocrine pancreas islets of Langerhans and scattered endocrine cells in the exocrine pancreas (Fig 3D) also expressed hK13.



View larger version (99K):
[in this window]
[in a new window]
 
Figure 3. (A) Cytoplasmic hK13 immunoexpression in hyperplastic follicles of the thyroid gland, MAb clone 2–17. (B) Cytoplasmic hK13 immunostaining in cells of the parathyroid glands, MAb clone 2–17. (C) Strong hK13 staining in the Leydig cells and weak staining in the atrophic spermatic epithelium of the testis, MAb clone 11C1. (D) Strong and diffuse hK13 immunostaining in an islet of Langerhans and in scattered cells among unstained acinar cells in the pancreas, MAb clone 11C1. (E) hK13 immunoexpression in luteinized cells in the stroma of the ovary, polyclonal antibody. (F) hK13 immunoexpression in the trophoblastic cells of the placenta, polyclonal antibody. (G) Cytoplasmic hK13 immunoexpression in the secretory epithelium and in decidual cells of the endometrium, polyclonal antibody. (H) hK13 immunoexpression in the Hassall's corpuscles of the thymus, MAb clone 2–17. (I) Intense cytoplasmic hK13 immunoexpression in the chondrocytes of the hyaline cartilage, MAb clone 2–17. (J) Immunoexpression of hK13 in autonomic nerves and ganglia of the neurovascular bundles in close proximity to the prostate gland, MAb clone 11C1. (K) hK13 immunoexpression in neurons and glial cells of the brain cortex, MAb clone IIC1. (L) hK13 immunoexpression in neutrophils (endocervical mucosa), MAb clone 11C1. Magnifications x200.

A clear immunoreaction was also observed in the primordial follicles, the corpus luteum, and in sparse luteinized cells in the stroma of the ovary (Fig 3E). The trophoblastic cells of the placenta expressed this kallikrein in all phases of their development (Fig 3F). The decidual cells in the endometrium during pregnancy and in certain endocrine disorders were also positive (Fig 3G).

The Hassall's corpuscles of the thymus (Fig 3H) and the chondrocytes (Fig 3I) also expressed the kallikrein. Nerves and ganglia of the peripheral nervous system (Fig 3J) were strongly positive. In the central nervous system, both neurons and glial cells were positive (Fig 3K). Among the inflammatory cells, neutrophils expressed hK13 strongly (Fig 3L).

In short, hK13 was expressed by many glandular epithelia, by some endocrine organs, and by some specialized epithelia and cells.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

The human kallikrein 13 gene (KLK13) was cloned by using the positional candidate approach (Yousef et al. 2000 ). By employing reverse transcription-polymerase chain reaction analysis, it was reported that KLK13 is expressed in various tissues, including breast, prostate, salivary glands, testis, lung, heart, thymus, adrenal, colon, thyroid, and trachea (Diamandis et al. 2000b ; Yousef and Diamandis 2001 ; Yousef et al. 2000 ). In addition, using ELISA-based methodologies for hK13, we confirmed that this protein is present in tissue extracts from esophagus, tonsil, salivary glands, prostate, kidney, skin, trachea, ureter, testis, breast, lung, thyroid, and stomach (our unpublished data). Furthermore, hK13 protein was found at relatively high concentrations in biological fluids such as seminal plasma, amniotic fluid, milk of lactating women, follicular fluid, and cerebrospinal fluid (our unpublished data). This combined information is in accord with the IHC data presented here. It is clear that the hK13 protein is expressed in many human tissues and cannot be considered a tissue-specific marker. Among all the kallikreins, some have tissue-restricted specificity, including hK2 and hK3, which are highly expressed in the prostate and at much lower levels in other tissues. In general, our data presented here correlate well with the expression of human kallikreins 6 and 10, two kallikreins that have been immunohistochemically localized by using similar techniques (Petraki et al. 2001 , Petraki et al. 2002 ).

We report here that hK13 is expressed mainly by glandular epithelia, further suggesting that this protein is secreted. The finding of hK13 protein in seminal plasma, amniotic fluid, milk of lactating women, follicular fluid, and cerebrospinal fluid further supports this hypothesis. Among other kallikreins that have been identified, all are found in biological fluids, an indication that all members of this family are secreted serine proteases.

In the testis, we have demonstrated that Leydig cells and the spermatic epithelium express hK13 protein. In our previous work we described the identification of five new mRNA KLK13 splice variants, which are expressed only in human testis (Chang et al. 2001 ). We have also reported differential expression of the KLK13 gene in testicular cancer. Furthermore, the five splice variants appear to be downregulated or not expressed at all in testicular cancer. The physiological and pathobiological roles of hK13 protein in the testis warrant further investigation.

The hK13 protein is expressed at high levels in the pituitary, especially in lactotrophs and corticotrophs, and in epithelium-lined spaces of the intermediate lobe remnant, which are prolactin-immunoreactive. The same distribution was observed with hK6 and hK10 expression in our previous studies (Petraki et al. 2001 , Petraki et al. 2002 ). It is worth mentioning that another kallikrein, KLK1, has been found in the lactotrophs of the rat and in the human anterior pituitary (Jones et al. 1990 ; Vio et al. 1990 ). Furthermore, we found hK13 along with hK6 and hK10 in the islet cells of the human pancreas. Moreover, these kallikreins were expressed in the epithelium of the pancreatic ducts but not in the acinar cells of the exocrine pancreas. Pancreatic kallikrein (KLK1) has also been found in pancreatic cells, including the ß-cells of the pancreatic islets (Ole-MoiYoi et al. 1979 ; Pinkus et al. 1983 ). We have previously speculated that the presence of these proteolytic enzymes in the pituitary and the islet cells of pancreas may be related to their ability to degrade hormone precursors, an activity that has been attributed to many other proteolytic enzymes (Mason et al. 1983 ; Coughlin 1999 ). The expression of human kallikrein 13 in the salivary glands is expected, because all other identified kallikreins are also expressed in this tissue (Diamandis et al. 2000b ; Yousef and Diamandis 2001 ).

The expression of a few kallikreins in the CNS has been previously reported (Diamandis et al. 2000b ; Yousef and Diamandis 2001 ). Yamanaka et al. 1999 found KLK6 mRNA in mature oligodendrocytes and suggested that this protease may be important in the processes that occur after maturation of oligodendrocytes, such as myelination or turnover of the proteins in myelin. Furthermore, Little et al. 1997 detected positive hK6 immunostaining in monkey cortex cells lining the perimeter of cortical microvessels, in brains of human patients with Alzheimer's disease, and in microglial cells, indicating a role of this protease in brain disease. Furthermore, new knowledge about human kallikrein 6 suggests a role in neurodegenerative diseases (Diamandis et al. 2000c ; Ogawa et al. 2000 ; Okui et al. 2001 ; Bernett et al. 2002 ; Blaber et al. 2002 ; Gomis-Ruth et al. 2002 ). It will be useful to examine the involvement of hK13 and other kallikreins in human neurodegeneration.

We have previously reported expression of hK6 and hK10 in oxyphylic cells in the thyroid and parathyroid glands. The expression of hK13 in these tissues is similar. Previously, the presence of hK2 and hK3 in the thyroid has been reported (Magklara et al. 2000 ).

Many kallikreins have found important applications as cancer biomarkers, including hK2 and hK3 for prostate cancer (McCormack et al. 1995 ; Chu 1997 ; Rittenhouse et al. 1998 ), hK6 and hK10 for ovarian carcinoma (Anisowicz et al. 1996 ; Diamandis et al. 2000d ; Luo et al. 2001a ), and hK11 for ovarian and prostate carcinoma (Diamandis et al. 2002 ). The availability of a sensitive method for measuring hK13 in biological fluids will allow examination of this protein as a disease biomarker. Moreover, the expression of multiple kallikreins in normal and cancerous tissues has prompted us to speculate that multiple members of this gene family may participate in cascade enzymatic reactions, similarly to the coagulation and apoptotic cascades. The localization of the three aforementioned kallikreins (hK6, hK10, and hK13) in the same types of human cells, as well as their hormonal regulation (Diamandis et al. 2000b ; Yousef and Diamandis 2001 ), further supports this hypothesis.

In summary, we describe for the first time the IHC localization of hK13 in various human tissues. Further studies will be necessary to examine the physiological and pathobiological role of this protein in these tissues.

Received for publication July 26, 2002; accepted November 6, 2002.
  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R (1996) A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2:624-636[Medline]

Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M (2002) Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 277:24562-24570[Abstract/Free Full Text]

Blaber SI, Scarisbrick IA, Bernett MJ, Dhanarajan P, Seavy MA, Jin Y, Schwartz MA et al. (2002) Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41:1165-1173[Medline]

Black MH, Diamandis EP (2000) The diagnostic and prognostic utility of prostate specific antigen for diseases of the breast. Breast Cancer Res Treat 59:1-4[Medline]

Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJ, Tindall DJ, Young CY et al. (2000) Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumors and in normal breast secretions. Br J Cancer 82:361-367[Medline]

Bhoola KD, Figueroa CD, Worthy K (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80[Medline]

Chang A, Yousef GM, Jung K, Rajpert–de Meyts E, Diamandis EP (2001) Identification and molecular characterization of five novel kallikrein gene (KLK13; KLK14) splice variants: differential expression in the human testis and testicular cancer. Anticancer Res 21:3147-3152[Medline]

Chu TM (1997) Prostate-specific antigen and early detection of prostate cancer. Tumor Biol 18:123-134

Coughlin SR (1999) How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96:11023-11027[Abstract/Free Full Text]

Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L et al. (2002) Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 62:295-300[Abstract/Free Full Text]

Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS et al. (2000a) New nomenclature for the human tissue kallikrein gene family. Clin Chem 46:1855-1858[Free Full Text]

Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV (2000b) The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 11:54-60[Medline]

Diamandis EP, Yousef GM, Petraki C, Soosaipillai AR (2000c) Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin Biochem 33:663-667[Medline]

Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P (2000d) Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 33:579-583[Medline]

Gomis–Ruth FX, Bayes A, Sotiropoulou G, Pampalakis G, Tsetsenis T, Villegas V, Aviles FX et al. (2002) The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J Biol Chem 277:27273-27281[Abstract/Free Full Text]

Jones TH, Figueroa CD, Smith C, Cullen DR, Bhoola KD (1990) Characterization of a tissue kallikrein in human prolactin-secreting adenomas. J Endocrinol 124:327-331[Abstract]

Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, Xing X, et al. (in press) Human kallikrein 13: Production and purification of recombinant protein, monoclonal and polyclonal antibodies and development of a sensitive and specific immunofluorometric assay. Clin Chem

Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR et al. (1997) Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 272:25135-25142[Abstract/Free Full Text]

Luo L-Y, Bunting P, Scorilas A, Diamandis EP (2001a) Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta 306:111-118[Medline]

Luo LY, Grass L, Howarth DJC, Thibault P, Ong H, Diamandis EP (2001b) Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 47:237-246[Abstract/Free Full Text]

Magklara A, Cheung CC, Asa SL, Diamandis EP (2000) Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clin Chim Acta 300:171-180[Medline]

Mason AJ, Evans BA, Cox DR, Shine J, Richards RI (1983) Structure of mouse kallikrein gene family suggests a role in specific processing of biological active peptides. Nature 303:300-307[Medline]

McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H et al. (1995) Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45:729-744[Medline]

Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Fujino Y et al. (2000) Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci 54:419-426[Medline]

Okui A, Kominami K, Uemura H, Mitsui S, Yamaguchi N (2001) Characterization of a brain-related serine protease, neurosin (human kallikrein 6), in human cerebrospinal fluid. Neuroreport 12:1345-1350[Medline]

Ole–MoiYoi OK, Pinkus GS, Spragg J, Austen KF (1979) Identification of human glandular kallikrein in the beta cell of the pancreas. N Engl J Med 300:1289-1294[Abstract]

Petraki C, Karavana VN, Luo LY, Diamandis EP (2002) Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem 50:1247-1261[Abstract/Free Full Text]

Petraki C, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJC, Yousef GM, Diamandis EP (2001) The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues, as assessed by immunohistochemistry. J Histochem Cytochem 49:1431-1442[Abstract/Free Full Text]

Pinkus GS, Maier M, Seldin DC, Ole–MoiYoi OK, Austen KF, Spragg J (1983) Immunohistochemical localization of glandular kallikrein in the endocrine and exocrine human pancreas. J Histochem Cytochem 31:1279-1288[Abstract]

Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW (1998) Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35:275-368[Medline]

Vio CP, Roa JP, Silva R, Powers CA (1990) Localization of immunoreactive glandular kallikrein in lactotrophs of the rat anterior pituitary. Neuroendocrinology 51:10-14[Medline]

Yamanaka H, He X, Matsumoto K, Shiosaka S, Yoshida S (1999) Protease M/neurosin mRNA is expressed in mature oligodendrocytes. Brain Res Mol Brain Res 71:217-224[Medline]

Yousef GM, Chang A, Diamandis EP (2000) Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275:11891-11898[Abstract/Free Full Text]

Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrine Rev 22:184-204[Abstract/Free Full Text]

Yousef GM, Luo LY, Diamandis E (1999) Identification of novel human kallikrein-like genes on chromosome 19q13.3–q13.4. Anticancer Res 19:2843-2852[Medline]